Antimicrobial ReportsRhizopus Infection in a Preterm Infant A Novel Use of PosaconazoleFatemizadeh, Roxana MD*; Rodman, Emily PharmD, BCPPS*,†; Demmler-Harrison, Gail J. MD*; Dinu, Daniela MD*Author Information From the *Department of Pediatrics, Baylor College of Medicine, Houston, Texas †Department of Pharmacy, Texas Children’s Hospital, Houston, Texas. Accepted for publication November 11, 2019. The authors have no funding or conflicts of interest to disclose. Address for correspondence: Daniela Dinu, MD, Department of Pediatrics, Section of Neonatology, Baylor College of Medicine, 6621 Fannin St, MC WT 6104, Houston, TX 77030. E-mail: firstname.lastname@example.org. The Pediatric Infectious Disease Journal: April 2020 - Volume 39 - Issue 4 - p 310-312 doi: 10.1097/INF.0000000000002554 Buy Metrics Abstract Posaconazole is a triazole antifungal with activity against Rhizopus, but data on its use and pharmacokinetics in preterm infants are scarce. In this case, a 24 4/7-week neonate’s Rhizopus infection is successfully treated with debridement and combination antifungal therapy with amphotericin B, micafungin and enteral posaconazole. This is the first reported posaconazole use in a preterm neonate with Rhizopus. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.